HCW Biologics Inc. (HCWB): Nasdaq/NYSE listing notice — Nasdaq panel grants HCW Biologics extension to July 29, 2026 to regain $1 bid price compliance

HCW Biologics Inc.

Must demonstrate bid price at or above $1 for 20 consecutive trading days by July 29, 2026.
If deficient before September 22, 2026, Company will be immediately delisted.
Non-compliance with any other listing rule before Sep 22 gives 7 days to advise panel.
Regaining compliance will result in a Discretionary Panel Monitor for one year.
Company's hearing was on May 5, 2026; panel granted extension on May 29, 2026.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

HCW Biologics Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

ng the exception period that may affect the Company’s compliance with Nasdaq requirements. If the Company regains compliance and satisfies the terms of the exception, the Panel intends to impose a Discretionary Panel Monitor on the Company for an additional one-year period, pursuant to Listing Rule 5815(d)(4)(A). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HCW BIOLOGICS INC. Date: June 1, 2026 By: /s/ Hing C. Wong Hing C. Wong, Founder and Chie

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

HCW Biologics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-026529

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.